7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 
      
    		                    
      cash flows from operating activities
    		                    
      net income
    		50,865,000 39,776,000 45,560,000 49,475,000 46,093,000 11,591,000 38,334,000 26,607,000 38,461,000 34,300,000 29,485,000 48,509,000 87,943,000 23,531,000 21,485,000 22,714,000 -9,620,000 14,117,000 7,386,000 -208,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                    
      depreciation
    		7,000 6,000 7,000 6,000 7,000 91,000 163,000 164,000 144,000 103,000 103,000 107,000 101,000 94,000 117,000 117,000 99,000 100,000 100,000 100,000 
      intangible amortization
    		5,961,000 5,961,000 5,961,000 5,962,000 5,961,000 5,961,000 5,961,000 5,961,000 5,962,000 5,961,000 5,961,000 5,961,000 5,962,000 5,961,000 5,082,000 4,643,000 4,573,000 4,629,000 4,579,000 4,283,000 
      acquired in-process research & development (ipr&d) expense
    		15,000,000   1,000,000 0                
      stock-based compensation
    		                    
      stock appreciation rights market adjustment
    		-145,000 -61,000 -49,000 -216,000 400,000 -125,000 40,000 32,000 -34,000 145,000 -642,000 411,000 -40,000 93,000 268,000 185,000 391,000 -80,000 -50,000 101,000 
      debt issuance costs amortization
    		161,000 163,000 166,000 169,000 175,000 176,000 180,000 185,000 1,249,000 424,000 416,000 422,000 418,000 411,000 412,000 418,000 459,000 697,000 664,000 1,392,000 
      deferred taxes
    		-3,881,000 -6,485,000 -4,311,000 -6,712,000 -4,830,000 -14,279,000 -3,477,000 1,123,000 -6,907,000 -4,193,000 -3,442,000 -4,264,000         
      amortization of premiums and accretion of discounts on investment securities
    		-336,000 -453,000 -451,000 -491,000 -550,000 -626,000 -594,000 -684,000 -719,000 -676,000 -636,000          
      other non-cash expenses
    		-9,000 465,000 467,000 481,000 493,000 659,000 467,000 510,000 459,000 430,000 369,000 484,000 272,000        
      change in operating assets and liabilities:
    		                    
      trade receivables
    		-7,670,000 12,988,000 -22,936,000 -1,531,000 1,655,000 -3,438,000 -5,579,000 -6,876,000 -3,452,000 -11,237,000 2,165,000 325,000 -5,243,000 -11,689,000 -3,290,000 -1,637,000 -2,011,000 -7,580,000 -1,439,000 -5,851,000 
      inventory
    		-782,000 284,000 814,000 -283,000 -1,272,000 214,000 -494,000 -276,000 -233,000 -764,000 207,000 -397,000 308,000 389,000 -165,000 373,000 146,000 -546,000 -582,000 -1,512,000 
      prepaid expenses and other assets
    		12,528,000 -3,587,000 -1,999,000 1,843,000 -847,000 -565,000 -3,439,000 1,833,000 -3,986,000 1,635,000 592,000 -3,069,000 -772,000 -1,472,000 -2,235,000 2,124,000 -3,093,000 -326,000 -296,000 1,606,000 
      trade payables
    		-1,960,000 10,842,000 3,715,000 3,212,000 -12,151,000 6,141,000 -2,586,000 6,196,000 -24,000 149,000 2,628,000 -6,263,000 3,388,000 -243,000 5,903,000 -3,178,000 2,173,000 -2,385,000 1,835,000 -6,791,000 
      other liabilities
    		28,026,000 -7,027,000 -5,456,000 12,575,000 24,319,000 -16,866,000 -8,229,000              
      net cash from operating activities
    		108,734,000 79,327,000 33,987,000 75,562,000 70,501,000 42,617,000 31,141,000 76,665,000 63,100,000 37,063,000 42,559,000 26,678,000 55,205,000 33,731,000 28,852,000 37,533,000 30,424,000   10,047,000 
      capex
    		-71,000 -4,000 -128,000 -513,000 -3,000 -632,000 -5,000 -107,000 0 0 0 0 -86,000 -41,000 -45,000 0 -93,000   0 
      free cash flows
    		108,663,000 79,323,000 33,859,000 75,049,000 70,498,000 41,985,000 31,136,000 76,558,000 63,100,000 37,063,000 42,559,000 26,678,000 55,119,000 33,690,000 28,807,000 37,533,000 30,331,000   10,047,000 
      cash flows from investing activities:
    		                    
      purchase of investment securities
    		-24,281,000 -23,900,000 -19,132,000 -35,685,000 -23,287,000 -21,211,000 -25,106,000 -21,613,000 -33,009,000 -25,071,000 -47,776,000 -55,092,000 -33,231,000        
      proceeds from maturities and sales of investment securities
    		19,563,000 19,315,000 21,622,000 30,011,000 24,035,000 25,556,000 18,925,000 22,622,000 32,196,000 17,505,000 45,986,000 8,197,000         
      purchase of property and equipment
    		-71,000 -4,000 -128,000 -513,000 -3,000 -632,000 -5,000 -107,000 0   0 -86,000 -41,000 -45,000 0 -93,000 -201,000 -4,000 0 
      acquisition of epygenix therapeutics, inc., net of cash acquired
    		   0 0                
      payment of upfront fee related to research collaboration, option and license agreement
    		0                    
      net cash from investing activities
    		-4,789,000 -19,589,000 2,362,000 -7,187,000 745,000 -54,856,000 -6,186,000 -36,065,000 -813,000 -7,771,000 -1,790,000 -46,895,000 -32,445,000 -22,447,000 -40,045,000 0 -93,000 -201,000 -100,004,000 -2,000,000 
      cash flows from financing activities:
    		                    
      principal repayment of long-term debt
    		-3,750,000 -3,750,000 -3,750,000 -3,750,000                 
      payments of employee withholding taxes related to stock-based awards
    		0 -1,033,000 -1,308,000 -2,228,000 0   0 0            
      proceeds from exercised options
    		754,000 2,097,000 4,706,000 3,237,000 2,575,000 573,000 116,000 227,000 244,000 675,000 3,909,000 3,566,000 2,142,000 1,250,000 1,883,000 7,577,000 1,134,000 648,000 12,000 16,000 
      net cash from financing activities
    		-2,996,000 -2,686,000 -352,000 -2,741,000 -1,175,000 -3,446,000 -3,634,000 -53,523,000 -55,099,000 -339,000 3,409,000 2,658,000 2,050,000 750,000 1,383,000 7,072,000 -313,000 648,000 12,000 -1,156,000 
      net increase in cash, cash equivalents, and restricted cash
    		100,949,000 57,052,000 35,997,000 65,634,000 70,071,000 -15,685,000 21,321,000 -12,923,000 7,188,000 28,953,000 44,178,000 -17,559,000 24,810,000   44,605,000 30,018,000 18,517,000 -87,462,000 6,891,000 
      cash, cash equivalents, and restricted cash—beginning of period
    		0 0 453,271,000 0 0 0 311,930,000 0 0 0 244,534,000 0 0 0 235,059,000 0 0 0 229,381,000 0 
      cash, cash equivalents, and restricted cash—end of period
    		100,949,000 57,052,000 489,268,000 65,634,000 70,071,000 -15,685,000 333,251,000 -12,923,000 7,188,000 28,953,000 288,712,000 -17,559,000 24,810,000 12,034,000 225,249,000 44,605,000 30,018,000 18,517,000 141,919,000 6,891,000 
      supplemental disclosure of cash flow information:
    		                    
      cash paid during the year for interest
    		3,508,000 3,463,000 4,197,000 4,147,000 4,226,000 4,359,000 4,585,000 4,398,000 4,962,000 5,674,000 5,017,000 5,030,000 3,810,000 3,695,000 3,829,000 3,833,000 2,905,000 6,582,000 6,510,000 6,654,000 
      cash paid during the year for taxes
    		59,000   21,086,000 16,456,000   11,690,000 16,653,000            
      stock-based and employee stock purchase compensation expense
    		 11,455,000 12,499,000 10,072,000 11,048,000 11,088,000 10,394,000 8,863,000 7,991,000 7,648,000 7,203,000 7,260,000 7,007,000 7,278,000 4,628,000 4,198,000 4,253,000    
      loss on debt extinguishment
    		       0        0    0 
      acquisition of zynerba pharmaceuticals, inc., net of cash acquired
    		                    
      payment of license fee and milestone
    		                    
      proceeds from long-term debt
    		                    
      debt issuance costs
    		       0        -5,000    0 
      extinguishment of debt
    		       0        0    0 
      extinguishment of debt exit fees
    		       0        0    0 
      repurchase of common stock
    		       -50,000,000            0 
      payment of license fee
    		    0                
      principal repayment of long term debt
    		     -3,750,000 -3,750,000 -3,750,000 0 -500,000 -500,000 -500,000 -500,000 -500,000 -500,000      
      accrued expenses and other current liabilities
    		       30,765,000 14,425,000 3,139,000 -1,850,000 -22,601,000 37,764,000 8,993,000 -3,586,000 7,802,000 6,855,000 5,542,000 -2,936,000 10,712,000 
      other non-current liabilities
    		       2,000 -2,000   0 1,000 0 -152,000 -162,000 53,000 -5,000 -32,000 127,000 
      milestone payments
    		           0 0 0 -40,000,000 0     
      proceeds from issuance of common stock
    		               0     
      common stock issuance costs
    		               0     
      proceeds from issuance of debt
    		                    
      proceeds from long term debt
    		               0    0 
      warrant expense
    		                   0 
      proceeds from issuance of common stock upon initial public offering
    		                   0 
      initial public offering issuance costs
    		                   -1,172,000 
      tax payments for employees shares withheld
    		                   0 
      supplemental disclosures of noncash investing and financing activities:
    		                    
      series a preferred stock accrued return
    		                   0 
      series a accretion of issuance costs
    		                   0 
      series b preferred stock accrued return
    		                   0 
      series b accretion of issuance costs
    		                   0 
      series c preferred stock accrued return
    		                   0 
      series c accretion of issuance costs
    		                   0 
      warrant financing
    		                   0 
      warrant liability reclassified to equity
    		                   0 
      investment securities interest income
    		                    
      non-cash lease expense
    		              385,000      
      net decrease in cash, cash equivalents, and restricted cash
    		              -9,810,000      
      milestones associated with acquired in-process research & development
    		                    
      noncash paid-in-kind interest expense
    		                    
      other non-current assets
    		                   1,265,000 
      proceeds from issuance of preferred stock
    		                    
      preferred stock issuance costs
    		                    
      milestone and acquisition of intangible asset
    		                 0 -100,000,000  
      cash paid during the year for milestones
    		                 0 100,000,000  
      stock-based compensation expense
    		                  3,301,000 2,823,000 
      net provided by (cash used) in operating activities
    		                  12,530,000  
      milestone associated with acquired in-process research & development
    		                    
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.